UROKINASE-SPECIFIC INHIBITORS AS ANTI-METASTATIC AGENTS

尿激酶特异性抑制剂作为抗转移剂

• 批准号: 3492756
• 负责人: HUGH H VARNER
• 金额: $ 5万
• 依托单位: BALTIMORE BIOTECH, INC.
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-09-15 至 1992-03-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3492756
• 关键词: amiloride; antineoplastics; combination cancer therapy; disease /disorder model; drug design /synthesis /production; histopathology; laboratory mouse; melanoma; metastasis; neoplasm /cancer chemotherapy; neoplastic cell; plasminogen activator; protease inhibitor; pyrazines

Urokinase-like plasminogen activator (uPA) has been implicated in tissue remodeling during such processes as tumor metastasis, wound healing and embryological development. Specific inhibitors of uPA have been developed which will be assayed as inhibitors of experimental metastasis in a mouse melanoma model system. Confirmation of a correlation between the uPA inhibitory and anti-metastatic properties of the compounds will be sought, as will information relating the inhibitors' structural features to their efficacy in vivo. The eventual outcome of confirmation of the efficacy of the drugs tested as anti-metastatic agents is intended to be the identification of a therapeutic agent or agents which will be useful in all cases of diagnosed solid tumors in humans as prophylaxis against metastasis.

尿激酶型纤溶酶原激活物(UPA)与组织 在肿瘤转移、伤口愈合和其他过程中的重构 胚胎发育。已经开发出了uPA的特异性抑制剂 这将作为小鼠实验性转移的抑制物进行测试 黑色素瘤模型系统。确认UPA与UPA之间的关联 将寻求化合物的抑制和抗转移特性， 将抑制剂的结构特征与它们的 体内药效。最终疗效的确认结果。 被测试为抗转移药物的药物旨在成为 确定一种或多种对所有人都有用的治疗剂 诊断为人类实体瘤的病例作为预防措施 转移。